Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 105, Issue 9, Pages -
Publisher
The Endocrine Society
Online
2020-06-03
DOI
10.1210/clinem/dgaa321
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?
- (2020) Ruth L. Coleman et al. DIABETES OBESITY & METABOLISM
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry
- (2019) Wenjun Fan et al. DIABETES OBESITY & METABOLISM
- Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults
- (2019) Sridharan Raghavan et al. Journal of the American Heart Association
- Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
- (2019) Subodh Verma et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
- (2019) Matthew M. Y. Lee et al. Current Atherosclerosis Reports
- Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study
- (2019) Peter Gæde et al. DIABETOLOGIA
- The Microalbuminuria Education Medication and Optimisation ( MEMO ) study: 4 years follow‐up of multifactorial intervention in high‐risk individuals with type 2 diabetes
- (2019) W. Crasto et al. DIABETIC MEDICINE
- Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
- (2019) David Fitchett et al. EUROPEAN HEART JOURNAL
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial
- (2019) Simon J Griffin et al. Lancet Diabetes & Endocrinology
- Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes
- (2018) David A. McAllister et al. CIRCULATION
- Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
- (2018) Kamlesh Khunti et al. DIABETES OBESITY & METABOLISM
- Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis
- (2018) Kamlesh Khunti et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
- (2018) Bernard Zinman et al. DIABETOLOGIA
- Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
- (2018) Jens Oellgaard et al. DIABETOLOGIA
- Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
- (2018) Subodh Verma et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2018) David Fitchett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study
- (2018) Shota Hamada et al. BMJ Open
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- (2018) Robert M Bell et al. Lancet Diabetes & Endocrinology
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare
- (2017) Karice K Hyun et al. HEART
- Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
- (2017) Kohjiro Ueki et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS)
- (2016) Favel L. Mondesir et al. AMERICAN HEART JOURNAL
- Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
- (2016) Peter Gæde et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Steno-2 — a small study with a big heart
- (2016) Harpreet Bajaj et al. Nature Reviews Endocrinology
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCLINICAL PERSPECTIVE
- (2015) Matthew A. Cavender et al. CIRCULATION
- Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes
- (2015) Isabelle Johansson et al. HEART
- Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events
- (2015) Jamal S. Rana et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Comprehensive Cardiovascular Risk Factor Control Improves Survival
- (2015) Vera Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: The randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study
- (2014) Anne Pernille Ofstad et al. AMERICAN HEART JOURNAL
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- (2014) Bernard Zinman et al. Cardiovascular Diabetology
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
- (2014) John J V McMurray et al. Lancet Diabetes & Endocrinology
- Independent Contribution of A1C, Systolic Blood Pressure, and LDL Cholesterol Control to Risk of Cardiovascular Disease Hospitalizations in Type 2 Diabetes: An Observational Cohort Study
- (2013) Gregory A. Nichols et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis
- (2011) Davide Castagno et al. AMERICAN HEART JOURNAL
- Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
- (2011) Adrian V. Hernandez et al. American Journal of Cardiovascular Drugs
- Sex/Gender Differences in Cardiovascular Disease Prevention
- (2011) Lori Mosca et al. CIRCULATION
- Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register
- (2011) S. Gudbjörnsdottir et al. DIABETOLOGIA
- Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial
- (2011) Simon J Griffin et al. LANCET
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial
- (2009) S. Zoungas et al. DIABETES CARE
- Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR)
- (2009) Jan Cederholm et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin
- (2009) Juhaeri Juhaeri et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Applying the Evidence
- (2009) Gustavo Saposnik et al. STROKE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now